NRX Pharmaceuticals, Inc. (NRXP)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about NRX Pharmaceuticals, Inc. (NRXP)
Company Performance

Current Price

as of Oct 16, 2024

$1.23

P/E Ratio

N/A

Market Cap

$13.22M

Description

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Metrics

Overview

  • HQWilmington, DE
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerNRXP
  • Price$1.23+2.50%

Trading Information

  • Market Cap$13.22M
  • Float73.49%
  • Average Daily Volume (1m)89,831
  • Average Daily Volume (3m)85,851
  • EPS-$2.75

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$7.90M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$7.05M
  • EV$32.36M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-15)
8-K (2024-10-11)
8-K (2024-08-20)
8-K (2024-08-15)
8-K (2024-08-14)
8-K (2024-08-12)
8-K (2024-06-27)
8-K (2024-06-20)
8-K (2024-05-23)
8-K (2024-05-16)
8-K (2024-04-30)
8-K (2024-04-19)
8-K (2024-04-15)
8-K (2024-04-02)
8-K (2024-03-28)
8-K (2024-03-21)
8-K (2024-03-06)
8-K (2024-02-28)
8-K (2024-02-14)
8-K (2024-02-02)
8-K (2024-01-23)
8-K (2023-12-29)
8-K (2023-12-21)
8-K (2023-11-21)
8-K (2023-11-14)
8-K (2023-10-23)
8-K (2023-09-14)
8-K (2023-09-01)
8-K (2023-08-31)
8-K (2023-08-14)
8-K (2023-07-28)
8-K (2023-06-06)
8-K (2023-06-05)
8-K (2023-04-21)
8-K (2023-03-31)
8-K (2023-03-13)
8-K (2023-03-09)
8-K (2023-03-03)
8-K (2023-02-24)
8-K (2023-02-23)
8-K (2023-02-13)
8-K (2023-02-02)
10-Q (2024-08-14)
10-Q (2024-05-14)
10-Q (2023-11-14)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-K (2024-03-29)
10-K (2023-03-31)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-14)
Earnings Report (2023-08-14)
Factset
Factset Business Description
Factset Street Account
StreetAccount Earnings Call Q&A Summary: NRX Pharmaceuticals Q3 (2023-11-23T09:17:35Z)
NRx Pharmaceuticals signs agreement accessing key data demonstrating efficacy and safety of IV Ketamine for the treatment of suicidal depression ($0.42, 0.00) (2023-12-19T13:18:28Z)
NRX Pharmaceuticals reports Q3 EPS ($0.07) vs FactSet ($0.11) [3 est, ($0.12)-(0.10)] ($0.34, 0.00) (2023-11-13T23:48:00Z)
NRx Pharmaceuticals announces strategic change in development of NRX-100 (IV Ketamine) ($0.28, 0.00) (2023-10-12T11:02:46Z)
NRx Pharmaceuticals announces further alignment with FDA on initiation of registrational trials for NRX-101 in the treatment of chronic pain ($0.26, 0.00) (2023-10-26T10:55:10Z)
NRx Pharmaceuticals announces FDA permission to proceed on IND application for NRX-101 to treat chronic pain ($0.26, 0.00) (2023-10-02T10:51:23Z)
NRx Pharmaceuticals and Nephron Pharmaceuticals announce joint agreement to develop IV Ketamine to treat suicidal depression ($0.33, 0.00) (2023-11-06T11:49:45Z)